Therapeutic Antibodies – Multimedia

Download this tech note to learn how mass spectrometry has gained substantial popularity for therapeutic mAb monitoring in clinical laboratories due to its great versatility to detect both tryptic peptides and intact light and heavy chains quantitatively.

In the “Quality by Design” approach for monoclonal antibody (mAb)-based therapeutics development, stability characterization—the probability of a protein unfolding—is performed to ensure that structure and function are preserved throughout development and manufacturing.

Glycan and peptide mapping are key analytical methodologies for the structural characterization of therapeutic proteins such as monoclonal antibodies (mAbs).

In quantifying therapeutic peptides and proteins in biological matrices, traditional ELISA-only based techniques can suffer from high variability, narrow dynamic range, problems with selectivity and typically cannot use internal standards.

In less than 10 minutes, Professor Andrew Zydney covers: What are biopharmaceuticals? How do they differ from traditional small-molecule pharmaceuticals? How are they made? What factors might influence the high cost of biopharmaceuticals?

Speaking at The Landscape of Cancer Research 2021 online symposium, Tianzi Li delivered her talk on the discovery of novel targets and the use of antibodies in cancer therapy.

In recent years, therapeutic antibodies have become the predominant class of new drugs developed in order to combat different diseases including cancers and autoimmune diseases among others. Antibody drug discovery does not come without its challenges including screening, characterization and target identification.

Various autoimmune diseases (e.g., myasthenia gravis) are mediated by IgG autoantibodies. To address this mechanism of autoimmunity, researchers are exploring the therapeutic use of FcRn inhibitors in an effort to decrease the pathogenesis of IgG and develop new therapies.

In this infographic, we explore the pipeline of therapeutic antibody discovery, development and manufacturing, highlighting key advancements throughout.

Scientists at Scripps Research have devised a method that may be able to shortcut one of the big steps in modern vaccine development.